Van Der Baan, Frederieke H. External Entity


Sort by

Selected publications

  • No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.  Gynecologic Oncology. 2016 Information Resource GET IT
    Times cited: 2
  • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers.  Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2015 Academic Article GET IT
    Times cited: 6